Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 2

2(28.6%)

Phase 3

1(14.3%)

7Total

Phase 1(4)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05826990Phase 2Recruiting

A Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI

Role: lead

NCT03680352Phase 1Completed

Pharmacokinetics of Cefepime and AAI101 in Subjects With Renal Insufficiency and Healthy Subjects

Role: lead

NCT03680378Phase 1Completed

Lung Pharmacokinetics (PK) in Epithelial Lining Fluid (ELF)

Role: lead

NCT03687255Phase 3Completed

Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections

Role: lead

NCT03775668Phase 1Completed

Single Dose Mass Balance Study With C14 - Labeled AAI101 in Healthy Male Volunteers

Role: lead

NCT03685084Phase 1Completed

Investigation of AAI101 Safety, Tolerability & PK in Healthy Volunteers

Role: lead

NCT03680612Phase 2Completed

Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI

Role: lead

All 7 trials loaded